With the deployment of its MinoSuiteTM Pioneer platform at the Institut Pasteur, within the Dynamics of Host-Pathogen Interactions unit, headed by Dr. Jost Enninga, deep-tech startup Minos Biosciences has officially launched its Early Access Program.
The strategic collaboration between Minos Biosciences and the teams of Jost ENNINGA and Milena HASAN from the Institut Pasteur, partially funded by the French National Research Agency (ANR) (DynamicHostPathOMICS project - ANR-24-CE19-5557), aims to develop new antimicrobial approaches based on an unprecedented understanding of infection mechanisms.
MinoSuite™: a breakthrough in cell analysis
Single-cell analysis has revolutionized biomedical research over the last decade, and represents a market worth over 4 billion Euros by 2024, with very dynamic growth of almost 15% per year. Yet there are still technological impasses limiting the potential of current technologies. MinoSuiteTM, the solution developed by Minos Biosciences, marks a paradigm shift in the analysis of cells and their interactions. For the first time, MinoSuiteTM makes it possible, at cellular resolution, to decipher the molecular mechanisms underlying the behavior of cells in complex biological systems. Thanks to its unique, patented CAGE-tagTM microfluidic technology, MinoSuiteTM combines high-throughput dynamic tracking of cells by imaging and their molecular profiling by sequencing.
Serving cutting-edge biomedical research with a strong socio-economic impact
Analysing the molecular mechanisms underlying the progression of bacterial, viral or parasitic infections within infected cells is essential to combat infectious diseases in a targeted and effective way. The approach developed by Minos Biosciences makes it possible to meet these challenges, in the context of the persistent threat of global pandemics, the increase in drug-resistant infections and the growing burden of chronic infections.
"Dynamic monitoring of the interactions between infected cells and pathogens, combined with real-time molecular data on the cell's response to successive stages of infection, will enable us to understand the evolution of the response of infected cells and the heterogeneity of these responses from one cell to another. This understanding is key to guiding the development of new antimicrobial strategies and next-generation antibiotics. In view of the preliminary results already obtained with the Minos team, we look forward to deploying Minos technology in our laboratories", says Dr. Jost ENNINGA, Director of the Dynamics of Host-Pathogen Interactions unit at the Institut Pasteur (UMR3691).
About Minos Biosciences : www.minos.bio
